Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus

This was a post-hoc analysis of a 2-year, double-blind study of 2639 patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin monotherapy which assessed achievement of a composite endpoint of sustained HbA1c reduction (≤7.0% at Week 104 or ≥0.5% from baseline) with no weight gain and no hypoglycaemic events with alogliptin 12.5 mg and 25 mg daily or glipizide (≤20 mg daily), each added to metformin With an HbA1c target of ≤7.0%, 24.2% and 26.9% of patients treated with alogliptin 12.5 mg and 25 mg, respectively achieved the composite endpoint vs. 10.7% of patients treated with glipizide (both p<0.001). With a criterion of ≥0.5% decrease in HbA1c, the composite endpoint was reached in 22.5%, 25.2% and 10.4% of patients treated with alogliptin 12.5 mg, alogliptin 25 mg and glipizide, respectively. Odds ratios of achieving the composite endpoint favoured alogliptin in the primary analysis set and in all subgroups of patients. Patients with T2DM failing metformin monotherapy are more likely to achieve sustained glycaemic control with no hypoglycaemia or weight gain at 2 years with alogliptin than with glipizide. Trial no: NCT00856284.